10x Genomics (NASDAQ:TXG) Shares Gap Up After Better-Than-Expected Earnings

10x Genomics (NASDAQ:TXG) shares gapped up before the market opened on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $17.51, but opened at $19.24. 10x Genomics shares last traded at $19.2650, with a volume of 943,596 shares.

The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.The business had revenue of $166.03 million for the quarter, compared to the consensus estimate of $160.35 million. During the same quarter last year, the business posted ($0.40) EPS. The business’s revenue was up .6% on a year-over-year basis.

10x Genomics News Summary

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q4 results beat expectations — 10x reported revenue of $166.03M (vs. $160.35M est.) and a loss per share of ($0.13) versus consensus ($0.19), with revenue roughly flat year‑over‑year; investors view this as evidence of demand resilience. 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026
• Positive Sentiment: Earnings call / transcript highlighted the beat and management’s commentary on execution and product adoption (read for color on management’s tone and strategic priorities). 10x Genomics (TXG) Q4 2025 Earnings Transcript
• Positive Sentiment: New scientific collaboration (PharosAI) using 10x’s Xenium platform could expand long‑term addressable market in cancer research, a potential revenue driver beyond 2026. UK-Backed PharosAI Cancer Data Project Using Xenium Might Change The Case For Investing In 10x Genomics (TXG)
• Neutral Sentiment: FY‑2026 revenue guidance set at $600M–$625M, roughly in line with sell‑side consensus ($624.2M) — guidance reduces near‑term forecasting surprise but leaves upside dependent on execution. 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026
• Neutral Sentiment: Street reaction mixed — TD Cowen kept a Hold rating but raised the price target to $19, signaling cautious respect for the beat but limited conviction on upside. Maintaining a Neutral Hold: Solid Q4 Beat but Limited 2026 Growth Visibility and Valuation Upside
• Negative Sentiment: Management rolled out a new pricing strategy that analysts flagged as an “earnings test” — pricing changes could create near‑term volatility and make 2026 growth visibility more uncertain. 10X Genomics faces earnings test as new pricing strategy debuts
• Negative Sentiment: Analyst commentary emphasizes limited 2026 growth visibility and constrained valuation upside absent clearer top‑line acceleration — a reason some investors remain cautious despite the beat. Maintaining a Neutral Hold: Solid Q4 Beat but Limited 2026 Growth Visibility and Valuation Upside

Analyst Ratings Changes

TXG has been the subject of several recent research reports. UBS Group upped their price target on shares of 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. upped their target price on shares of 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Stifel Nicolaus set a $20.00 price target on 10x Genomics in a report on Friday. Zacks Research lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Finally, Leerink Partners lowered their target price on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research report on Tuesday, January 27th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.61.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 13,261 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $251,959.00. Following the transaction, the chief executive officer owned 1,021,556 shares in the company, valued at $19,409,564. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Taich sold 11,888 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $225,872.00. Following the transaction, the chief financial officer directly owned 297,385 shares of the company’s stock, valued at approximately $5,650,315. The trade was a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 33,432 shares of company stock worth $635,208 over the last quarter. 9.39% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Allworth Financial LP boosted its position in shares of 10x Genomics by 150.4% during the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock valued at $26,000 after purchasing an additional 1,364 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of 10x Genomics in the 4th quarter worth approximately $38,000. Larson Financial Group LLC lifted its stake in 10x Genomics by 164.4% during the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after purchasing an additional 1,470 shares during the last quarter. True Wealth Design LLC boosted its holdings in 10x Genomics by 1,552.5% during the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after buying an additional 3,369 shares in the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new position in 10x Genomics in the third quarter worth approximately $56,000. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Stock Up 12.5%

The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -31.77 and a beta of 2.24. The company’s 50-day simple moving average is $18.66 and its 200-day simple moving average is $15.57.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.